Search for: "CELGENE CORPORATION"
Results 1 - 12 of 12
Sorted by Relevance | Sort by Date
RSS Subscribe:  20 results  |  100 results
13 Jan 2:25 pm by Tom Lamb
... 16 reports of these serious skin rash conditions among patients who used Revlimid from December 2005 -- when this drug was first marketed by Celgene Corporation -- through June 2008. This letter to the editor was written by several Celgene employees, and is ... ] The letter goes on to discuss in some detail several of the SJS, TEN, and EM case reports that Celgene knows about thus far. In closing, the authors acknowledge that there is a possible cause-and-effect relationship between Revlimid and ...
Drug Injury Watch - http://www.drug-injury.com/druginjurycom/
29 Nov, 2007 1:00 am
... in a civil suit. Judge Leonard D. Wexler also vacated a 17-year-old injunction against the distributors, in effect ending the lawsuit." Corporate Governance Subscription Required ISS Policies for 2008 Promote Narrower Director Discretion Thursday, November 29, 2007 By David A. Katz and ... . Abu Dhabi will buy equity units, with mandatory conversion into common shares in 2010 and 2011. Also, New Jersey-based biotechnology company Celgene has purchased cancer drugmaker Pharmion for $2.9 billion."
New York Supreme Court Criminal Term Library Blog - http://www.bloglines.com/blog/PLL
27 Aug 3:22 pm by Stephen Albainy-Jenei
... $24 billion company. Jacobson has now brought a lawsuit against the Celgene Corporation (Jacobson v. Celgene Complaint) based on what she claims is Celgene's misappropriation of her idea for treating multiple myeloma with thalidomide ... to Beth Wolmer for her persistence in recommending the clinical evaluation of thalidomide in the treatment of multiple myeloma." In addition, Celgene's 1999 Annual Report stated that the 1999 clinical trial for the treatment of multiple myeloma with thalidomide along ...
Patent Baristas - http://www.patentbaristas.com/
27 Dec, 2006 7:18 am by Phil
... S. Food & Drug Administration (FDA) to manufacture and market a generic version of Celgene Corporation's Thalomid(R) (thalidomide) Capsules, 50 mg and 100 mg. ... the FDA on December 5, 2006. Following receipt of the notice from the FDA, Barr notified Celgene, the patent owner and New Drug Applications (NDA) holder. Also in December 2006 ... Capsules was invalid or would not be infringed by Barr's product. Barr notified Celgene of its challenge to the new patent. Thalomid Capsules, 50 mg, 100 mg and ...
Tags: Reverse, Payments
Philip Brooks' Patent Infringement Updates - http://infringement.blogs.com/philip_brooks_patent_infr/
2 Oct, 2008 10:58 am
... a successful clinical trial. In 1991, Dr. Gills Kaplan determined that Thalidomide inhibited tumor necrosis factor, and she partnered with Celgene Corporation to seek further development for Thalidomide. Later, Celgene developed Revlimid, a substantially more powerful analogue, having fewer side effects. Revlimid gained FDA approval as a new drug application (NDA) on December 27, 2005. Later, the FDA ...
West Palm Beach Personal Injury Lawyer - http://westpalmbeach.injuryboard.com/
4 Nov, 2007 7:03 pm by Donald Zuhn
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Celgene Corporation et al. v. Barr Laboratories, Inc. et al. 2:07-cv-05256; filed October 31, 2007 in the District Court...
Patent Docs - http://patentdocs.typepad.com/patent_docs/
11 Jul, 2008 4:30 am
... updated Patentscope ® includes Japanese as search language: (IPR-Helpdesk), (IP Menu News), Corporate managers: Are you failing to obtain maximum value from your energy savings and green ... combinations containing previously approved drugs: (FDA Law Blog), Thalomid (Thalidomide) - US: Celgene files another lawsuit accusing Barr of infringing its patents for Thalomid: (IP Law360), ... to clarify EU trade mark law: Case C-252/07 Intel Corporation v CPM United Kingdom: (Out-Law), CFI finds DREAM IT! DO IT ...
IP Thinktank - http://duncanbucknell.com/blog
12 Sep, 2008 2:33 pm
... is prior art information that could undermine Singulair patent: (Law360), Thalomid (Thalidomide) - US: Barr argues Celgene's patent claims unenforceable because inventor withheld material information during patent prosecution: (Law360), Xyzal ( ... System released - room for potential patent reform?: (IPRoo), Review of National Innovation System - Key points for corporate counsel: (Mallesons Stephen Jaques), Review of National Innovation System recommends creative commons: (creativecommons.org), ...
IP Thinktank - http://duncanbucknell.com/blog
20 Jun, 2008 8:07 am
... Docs), 23 June: STEP / Committee on National Statistics conference on 'Intangible assets: measuring and enhancing their contribution to corporate value and economic growth' - Washington: (IP finance), (IPKat), 24 June: ACID licensing seminar - London: (IPKat), ... Galantamine) - US: Janssen files patent suit against Sandoz over Galantamine ANDA: (IP Law360), Thalomid (Thalidomide) - US: Celgene loses bid to stay Barr's antitrust cross-claims in Thalomid patent suit: (IP Law360), Uroxatral (Alfuzosin) ...
IP Thinktank - http://duncanbucknell.com/blog
25 Jul, 2008 7:04 am
... tablets on day-1 in Japan: (GenericsWeb), Ritalin (Methylphenidate) - US: KV Pharmaceuticals loses bid for sanctions against Celgene and Novartis for failing to conduct infringement analysis before suing KV to stop it from marketing generic Ritalin: (IP ... Docs), (ISinIP), Nelson - Claims construction order in wide, short ski case brought by Paul Nelson against K2 Corporation: (Washington State Patent Law Blog), NeoMedia - EEF patent busting project: USPTO rejects all 95 NeoMedia patent claims ...
IP Thinktank - http://duncanbucknell.com/blog
2 Aug, 2008 12:54 am
... Proximagen Neuroscience strikes gold in deal for development and commercialisation of PRX1: (IP finance), Ritalin (Methylphenidate) - US: Celgene wins bid to have Buchanan Ingersoll disqualified from representing KV Pharmaceutical in longstanding patent dispute over Ritalin: ... appellate court rules on statute of limitations in third party trade secrets misappropriation case: Cypress Semiconductor Corporation v Superior Court (Silvaco Data Systems): (IP Law Blog) eBay - PerfumeBay.com disappears ...
IP Thinktank - http://duncanbucknell.com/blog
17 Feb 2:00 pm by Lucas A. Ferrara, Esq.
... Jersey Cocktail Hour--6:00 p.m. Dinner--7:00 p.m. Honoring: Sol Barer, Phd, CEO Celgene for Leadership in Transformational Medicine --Rich Bagger, Senior VP for Worldwide Public Affairs & Policy, Pfizer, and former New ... of the ticket price is a tax deductible charitable contribution.Center for Medicine in the Public Interest, is a New York not-for-profit corporation dedicated to charitable, religious, scientific, literary and educational purposes within the meaning of Section 501(c)(3) of the ...
Real Estate Law Blog - http://www.nyrealestatelawblog.com/
         
Add to your RSS Reader Add to your Google Add to your My Yahoo Add to your My MSN Add to your My AOL Add to your Feedster Add to your Newsgator Add to your Bloglines Add to your NewsBurst Add to your Rojo Add to your Pluck